AIM ImmunoTech Inc.
AIMHealthcare|Biotechnology|US
$0.15
+0.00 (+1.91%)
Tangible Book / Share
$0.35
Cash / Share
$0.58
Financials
Financial Snapshot
Market Cap
$6.2M
Enterprise Value
$204.7K
Revenue (TTM)
$95.0K
Net Income (TTM)
-$14.3M
Cash & Investments
$10.0M
Net Cash
$6.0M
Free Cash Flow (TTM)
-$7.2M
Operating CF (TTM)
-$7.1M
Debt/Equity
0.51
Cash Runway & Burn Rate
Cash on Hand
$10.0M
Quarterly Burn
$1.8M
Monthly Burn
$588.8K
Est. Runway
~5.6 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $5.9M | $2.1M | $1.8M | $8.8M | $39.0M | $48.3M | $34.2M | $13.1M | $4.0M | $993.0K | $10.0M | |
| Operating Cash Flow | -$7.4M | -$7.9M | -$10.6M | -$9.1M | -$10.4M | -$14.0M | -$16.1M | -$21.3M | -$14.9M | -$11.0M | -$7.1M | |
| Free Cash Flow | -$7.8M | -$8.0M | -$10.8M | -$9.4M | -$11.0M | -$14.0M | -$16.4M | -$21.9M | -$14.9M | -$11.3M | -$7.2M | |
| Capital Expenditure | -$454.0K | -$69.0K | -$127.0K | -$365.0K | -$595.0K | -$41.0K | -$271.0K | -$585.0K | -$18.0K | -$378.0K | -$95.0K | |
| Financing Cash Flow | $4.8M | $4.2M | $9.4M | $16.4M | $56.6M | $8.2M | $80.0K | $485.0K | $6.4M | $10.4M | $18.0M |
R&D Spending
R&D (TTM)
$2.7M
R&D Intensity
2885.3%
R&D Growth vs Prior
-30.1%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $92.0K | $437.0K | $367.0K | $140.0K | $163.0K | $135.0K | $141.0K | $202.0K | $170.0K | $88.0K | $95.0K | |
| R&D Expense | $5.1M | $4.1M | $4.8M | $4.7M | $5.7M | $7.7M | $7.0M | $10.9M | $6.2M | $3.9M | $2.7M | |
| R&D % of Revenue | 5551.1% | 937.8% | 1301.9% | 3322.1% | 3509.2% | 5683.0% | 4957.4% | 5408.4% | 3645.3% | 4459.1% | 2885.3% | |
| SG&A | $7.7M | $6.6M | $6.2M | $7.0M | $8.7M | $8.7M | $13.1M | $21.1M | $13.7M | $7.7M | $8.4M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $92.0K | $437.0K | $367.0K | $140.0K | $163.0K | $135.0K | $141.0K | $202.0K | $170.0K | $88.0K | $95.0K | |
| Cost of Revenue | $1.1M | $1.2M | $884.0K | $893.0K | $806.0K | $850.0K | $0.00 | $42.0K | $31.0K | $338.0K | $214.0K | |
| Gross Profit | -$1.0M | -$746.0K | -$517.0K | -$753.0K | -$643.0K | -$715.0K | $141.0K | $160.0K | $139.0K | -$250.0K | -$119.0K | |
| R&D | $5.1M | $4.1M | $4.8M | $4.7M | $5.7M | $7.7M | $7.0M | $10.9M | $6.2M | $3.9M | $2.7M | |
| SG&A | $7.7M | $6.6M | $6.2M | $7.0M | $8.7M | $8.7M | $13.1M | $21.1M | $13.7M | $7.7M | $8.4M | |
| Operating Income | -$13.8M | -$11.4M | -$11.5M | -$12.4M | -$15.2M | -$18.8M | -$19.9M | -$31.9M | -$19.8M | -$10.5M | -$11.1M | |
| Interest Expense | $0.00 | $139.0K | $502.0K | $427.0K | $672.0K | $67.0K | $0.00 | $0.00 | $585.0K | $812.0K | $1.1M | |
| Pretax Income | -$7.5M | -$8.3M | -$9.8M | -$9.4M | -$14.4M | -$19.1M | -$19.4M | -$29.0M | -$17.3M | -$14.0M | -$14.3M | |
| Net Income | -$7.5M | -$8.3M | -$9.8M | -$9.4M | -$14.4M | -$19.1M | -$19.4M | -$29.0M | -$17.3M | -$14.0M | -$14.3M | |
| EPS (Diluted) | -543.05 | -463.19 | -355.19 | -93.71 | -16.41 | -14.67 | -14.69 | -21.64 | -11.22 | -8.62 | -3.84 | |
| EBITDA | -$6.3M | -$7.1M | -$8.4M | -$8.2M | -$13.0M | -$18.3M | -$19.2M | -$28.7M | -$16.5M | -$12.9M | -$12.5M | |
| Shares Out. (M) | 0.01 | 0.02 | 0.03 | 0.10 | 0.88 | 1.30 | 1.32 | 1.34 | 1.54 | 1.62 | 17.12 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.4M | $1.4M | $299.0K | $1.5M | $38.5M | $32.1M | $27.1M | $5.4M | $1.7M | $931.0K | $9.9M | |
| Short-Term Investments | $3.5M | $695.0K | $1.5M | $7.3M | $501.0K | $16.2M | $7.1M | $7.6M | $2.3M | $62.0K | $64.0K | |
| Total Current Assets | $6.9M | $3.5M | $3.8M | $10.4M | $40.3M | $50.2M | $36.3M | $14.6M | $4.2M | $3.3M | $10.4M | |
| Total Assets | $18.9M | $14.2M | $13.8M | $20.2M | $111.0M | $57.7M | $40.5M | $19.4M | $8.6M | $5.8M | $12.7M | |
| Total Current Liabilities | $2.4M | $2.7M | $5.3M | $1.1M | $1.1M | $673.0K | $1.4M | $8.7M | $9.5M | $6.2M | $4.9M | |
| Long-Term Debt | $0.00 | $1.8M | $0.00 | $3.9M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $927.0K | $0.00 | |
| Total Liabilities | $3.4M | $5.5M | $8.7M | $7.3M | $49.7M | $820.0K | $2.0M | $9.1M | $9.9M | $15.6M | $5.0M | |
| Stockholders' Equity | $15.5M | $8.7M | $5.2M | $12.9M | $61.3M | $56.9M | $38.5M | $10.2M | -$1.3M | -$9.8M | $7.7M | |
| Retained Earnings | -$300.5M | -$308.8M | -$318.6M | -$328.1M | -$342.0M | -$361.1M | -$380.5M | -$409.5M | -$426.8M | -$440.8M | -$447.6M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.4M | -$7.9M | -$10.6M | -$9.1M | -$10.4M | -$14.0M | -$16.1M | -$21.3M | -$14.9M | -$11.0M | -$7.1M | |
| Capital Expenditure | -$454.0K | -$69.0K | -$127.0K | -$365.0K | -$595.0K | -$41.0K | -$271.0K | -$585.0K | -$18.0K | -$378.0K | -$95.0K | |
| Free Cash Flow | -$7.8M | -$8.0M | -$10.8M | -$9.4M | -$11.0M | -$14.0M | -$16.4M | -$21.9M | -$14.9M | -$11.3M | -$7.2M | |
| Investing Cash Flow | $2.9M | $2.7M | $92.0K | -$6.1M | -$9.2M | -$631.0K | $11.0M | -$832.0K | $4.7M | $1.9M | $52.0K | |
| Financing Cash Flow | $4.8M | $4.2M | $9.4M | $16.4M | $56.6M | $8.2M | $80.0K | $485.0K | $6.4M | $10.4M | $18.0M | |
| Issuance of Stock | $4.7M | $2.4M | $5.1M | $15.3M | $61.2M | $13.0M | $80.0K | $485.0K | $892.0K | $8.3M | $7.5M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | -$1.0K | $1.9M | $4.9M | $1.1M | -$4.7M | -$4.9M | $0.00 | $0.00 | $2.2M | $2.1M | $1.6M | |
| Stock Based Comp. | $410.0K | $571.0K | $929.0K | $853.0K | $1.0M | $1.6M | $954.0K | $243.0K | $686.0K | $60.0K | $0.00 | |
| Net Change in Cash | $293.0K | -$996.0K | -$1.1M | $1.2M | $37.0M | -$6.4M | -$5.0M | -$21.6M | -$3.7M | $1.3M | $10.9M |
Dilution Tracker
Shares outstanding grew 84.4% over 5 years — significant dilution
Shares Outstanding
40M
5-Year Share Growth
+84.4%
Stock Issuance (TTM)
$7.5M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.01 | 0.02 | 0.03 | 0.10 | 0.88 | 1.30 | 1.32 | 1.34 | 1.54 | 1.62 | 17.12 | |
| Change vs Prior % | — | 31.4% | 54.1% | 262.7% | 774.2% | 48.6% | 1.5% | 1.1% | 15.3% | 4.8% | 957.6% | |
| Stock Issuance | $4.7M | $2.4M | $5.1M | $15.3M | $61.2M | $13.0M | $80.0K | $485.0K | $892.0K | $8.3M | $7.5M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $410.0K | $571.0K | $929.0K | $853.0K | $1.0M | $1.6M | $954.0K | $243.0K | $686.0K | $60.0K | $0.00 |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | -1104.3% | -170.7% | -140.9% | -537.9% | -394.5% | -529.6% | 100.0% | 79.2% | 81.8% | -284.1% | -125.3% | |
| Operating Margin % | -15004.3% | -2612.4% | -3132.4% | -8887.9% | -9295.7% | -13954.1% | -14129.7% | -15800.0% | -11630.6% | -11961.4% | -11637.9% | |
| Net Margin % | -8154.3% | -1889.9% | -2673.8% | -6717.1% | -8834.4% | -14168.1% | -13790.8% | -14337.6% | -10188.2% | -15861.4% | -15021.1% | |
| EBITDA Margin % | -6883.7% | -1626.8% | -2301.6% | -5846.4% | -7972.4% | -13544.4% | -13609.2% | -14219.8% | -9699.4% | -14700.0% | -13120.0% | |
| FCF Margin % | -8515.2% | -1833.0% | -2933.8% | -6737.1% | -6725.8% | -10374.8% | -11616.3% | -10817.8% | -8768.2% | -12880.7% | -7536.8% | |
| ROE % | -48.4% | -94.9% | -189.7% | -72.9% | -23.5% | -33.6% | -50.5% | -283.0% | 1310.1% | 142.7% | 952.8% | |
| ROA % | -39.7% | -58.1% | -70.9% | -46.5% | -13.0% | -33.1% | -48.0% | -149.4% | -201.2% | -241.4% | -112.1% | |
| ROIC % | -84.0% | -99.3% | -94.5% | -64.3% | -13.8% | -33.0% | -50.7% | -291.4% | -1221.2% | -313.6% | -94.8% | |
| R&D / Revenue % | 5551.1% | 937.8% | 1301.9% | 3322.1% | 3509.2% | 5683.0% | 4957.4% | 5408.4% | 3645.3% | 4459.1% | 2885.3% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -30.8% | 375.0% | -16.0% | -61.9% | 16.4% | -17.2% | 4.4% | 43.3% | -15.8% | -48.2% | |
| Gross Profit | 30.6% | 26.6% | 30.7% | -45.6% | 14.6% | -11.2% | 119.7% | 13.5% | -13.1% | -279.9% | |
| Operating Income | 17.1% | 17.3% | -0.7% | -8.2% | -21.8% | -24.3% | -5.8% | -60.2% | 38.0% | 46.8% | |
| Net Income | 50.7% | -10.1% | -18.8% | 4.2% | -53.1% | -32.8% | -1.7% | -48.9% | 40.2% | 19.4% | |
| EPS (Diluted) | 52.8% | 14.7% | 23.3% | 73.6% | 82.5% | 10.7% | -0.2% | -47.3% | 48.1% | 23.2% | |
| Operating Cash Flow | 54.0% | -7.6% | -34.0% | 14.8% | -14.3% | -34.7% | -15.3% | -32.0% | 30.0% | 26.4% | |
| Free Cash Flow | 52.6% | -2.2% | -34.4% | 12.4% | -16.2% | -27.8% | -16.9% | -33.4% | 31.8% | 24.0% | |
| R&D Expense | -36.5% | -19.8% | 16.6% | -2.7% | 23.0% | 34.1% | -8.9% | 56.3% | -43.3% | -36.7% | |
| SG&A Expense | 7.5% | -14.4% | -5.6% | 13.5% | 22.9% | 0.2% | 50.8% | 61.7% | -35.1% | -43.9% | |
| Total Assets | -17.2% | -24.7% | -2.5% | 46.0% | 449.1% | -48.0% | -29.8% | -52.1% | -55.6% | -32.8% | |
| Book Value / Share | -31.4% | -57.3% | -61.4% | -31.2% | -45.7% | -37.6% | -33.4% | -73.7% | -111.2% | -605.9% | |
| Debt | -100.0% | 0.0% | 222.9% | 7.7% | -64.2% | -93.5% | 461.7% | -14.2% | 309.6% | 66.5% | |
| Diluted Shares | 10.9% | 31.4% | 54.1% | 262.7% | 774.2% | 48.6% | 1.5% | 1.1% | 15.3% | 4.8% |
Valuation
P/E (TTM)At Loss
P/S65.09
10Y Low / Med / High20.78 / 274.12 / 906.99
P/B0.34
10Y Low / Med / High0.40 / 2.52 / 5.42
EV/EBITDAAt Loss
EV/Revenue2.15
10Y Low / Med / High60.53 / 178.22 / 684.80
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$0.35
Net Current Assets / Share
$0.14
Graham Net-Net
$0.29
Cash / Share
$0.58
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -5.26 | -3.13 | -2.10 | -0.54 | -10.26 | -5.90 | -1.99 | -1.91 | -1.68 | -0.13 | -0.04 | |
| P/S Ratio | 424.36 | 59.57 | 56.21 | 36.45 | 906.99 | 836.65 | 274.12 | 274.43 | 170.93 | 20.78 | 65.09 | |
| P/B Ratio | 2.52 | 2.99 | 3.99 | 0.40 | 2.41 | 1.99 | 1.00 | 5.42 | -21.98 | -0.19 | 0.34 | |
| EV/EBITDA | -5.78 | -3.72 | -3.11 | -1.22 | -8.59 | -4.43 | -0.65 | -1.77 | -1.84 | -0.45 | -0.02 | |
| EV/Revenue | 398.18 | 60.53 | 71.54 | 71.52 | 684.80 | 600.03 | 88.19 | 251.06 | 178.22 | 65.84 | 2.15 |
Analyst Estimates & Quality
Altman Z-Score
-51.36
Distress
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $74.0K | $100.0K | $51.0M |
| Net Income | -$1.4M | -$874.1K | -$987.4K |
| EPS | $-0.86 | $-0.54 | $-0.61 |
| # Analysts (EPS) | 1 | 1 | 1 |
Revenue Segments
By Product
| Segment | 2021 | 2022 |
|---|---|---|
| Clinical Treatment Programs U S | $135.0K | — |
| Clinical Treatment Programs - US | — | $141.0K |
By Geography
| Segment | 2020 |
|---|---|
| Europe | $19.0K |
| United States | $144.0K |